On March 30, 2020 Diverse Biotech, Inc. www.diversebiotech.com reported it has signed an initial partnership agreement with The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center to study its potential new therapeutic candidates in glioblastoma (Press release, Diverse Biotech, MAR 30, 2020, View Source [SID1234576456]). The research will be performed in animal models of the disease to evaluate the efficacy and tissue distribution of Diverse Biotech’s new drug compounds.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to be partnering with this world-renowned center for the study and treatment of brain cancer. Glioblastoma is a disease with a large unmet patient need. Our team at Diverse Biotech wants to develop and study new drugs that could change the standard of care in this disease," said Stella Vnook, Diverse Biotech’s Chief Executive Officer.

"We are excited to be collaborating with Diverse Biotech and to evaluate their cannabidiol compounds in our GBM models. One of the main goals of our lab is to find new therapies that might improve the outcomes for patients living with this disease. Preclinical testing of novel agents is the first step in this process," said Steve Keir, DrPH, MPH, MMCI, Research Professor and Director of Translational Research at The Preston Robert Tisch Brain Tumor Center, Duke University.